A tissue cross-reactivity study is an immunohistochemical investigation for monoclonal antibodies and other suitable biopharmaceuticals. It examines whether the test substance binds to structures other than its intended target structure within a spectrum of human tissues. The study aims to detect unintended tissue reactivity and can support the selection of a pharmacologically relevant animal species for safety studies.<\/p>\n
According to ICH S6(R1), for monoclonal antibodies, antigenic specificity, complement binding, and any unintended reactivity or cytotoxicity to human tissues outside the target tissue must be described in detail. For this purpose, tissue cross-reactivity must be investigated using appropriate immunohistochemical methods on a range of human tissues. The result is a binding profile, not immediate proof of clinical toxicity.<\/p>\n
The interpretation therefore considers the location, intensity, and plausibility of binding. Staining must be evaluated with knowledge of the target antigen, method controls, and potential artifacts. The finding can establish a hypothesis regarding potential target organs, but pharmacological activity, exposure, and functional consequences must be assessed separately. Not every signal outside the desired tissue automatically leads to a safety risk in humans.<\/p>\n
For antibodies, an animal species is particularly informative if it expresses the desired epitope and exhibits a tissue cross-reactivity profile similar to humans. This allows for a better assessment of both target-mediated toxicity and unintended binding. A species without the target epitope may exceptionally be relevant for other aspects if it shows a pattern of unintended tissue reactivity comparable to humans.<\/p>\n
The FDA Addendum to ICH S6(R1) indicates that TCR investigations in animal tissue have limited value for species selection. If a pharmacologically relevant species cannot be determined by homology, affinity, and functional activity, comparing tissue binding in humans and animals can still contribute to selection. The study thus complements receptor and functional data, rather than replacing them.<\/p>\n
A tissue cross-reactivity study investigates the binding of the administered antibody to tissue structures. Immunogenicity, in contrast, describes the immune response of an organism to the active substance, particularly the formation of anti-drug antibodies. One concerns the potential target binding of the drug, the other the immune system’s reaction to this drug.<\/p>\n
The two questions may overlap in the development program but remain methodologically separate. TCR uses tissue sections and immunohistochemical detection methods; immunogenicity is assessed in biological samples after treatment. The existing entry on immunogenicity therefore does not address a substitute term for the investigation described here.<\/p>\n
The TCR study is particularly informative if the tissue panel includes potentially relevant organs and appropriate controls. The validity of the staining depends on the documentation of the detection chain, positive and negative controls, and the specificity of the observed signals. A different binding pattern between batches of the test material can also indicate product-related differences and should not be dismissed as a mere laboratory phenomenon.<\/p>\n
For antibody-drug conjugates, in addition to antibody binding, the drug component and linker can also contribute to toxicity. A TCR result primarily describes the binding behavior of the antibody component. The safety assessment must therefore include additional data, so that tissue staining is not prematurely used as a complete explanation or clearance for overall toxicity.<\/p>\n
Furthermore, a lack of staining in a single section does not necessarily mean that the organ in question remains completely risk-free in humans. Variations in antigen expression and the limitations of the methodology must be considered in the interpretation of findings before clinical monitoring measures are discontinued or supplemented.<\/p>\n
The investigation can also help to reveal differences between human and animal tissue patterns early on. This comparison explains why a safety finding from an animal model is either well transferable to humans or only interpretable to a limited extent.<\/p>\n
A notable TCR profile can influence the selection of clinical safety parameters, the presentation of potential target organs in the Investigator’s Brochure, and dose caution before first-in-human administration. For regulatory assessment, the test material, tissue panel, controls, evaluation criteria, and the connection to species selection must be traceable. Clinical monitoring should only be specifically expanded where the overall finding suggests a plausible function or burden.<\/p>\n
Full-service CROs like Mediconomics support the planning of the TCR study, the coordination of histopathology and nonclinical strategy, and the transfer of relevant findings into clinical risk management. Nonclinical Writing and Regulatory Affairs can consistently present the binding profile, species rationale, and derived monitoring measures.<\/p>\n
Does a TCR staining prove a clinical side effect?<\/strong><\/p>\n Staining does not provide this proof. It indicates potential binding and must be evaluated together with functional data, exposure, and other nonclinical findings.<\/p>\n Why are human tissues used?<\/strong><\/p>\n The investigation aims specifically to detect unexpected binding to human structures outside the desired therapeutic target.<\/p>\n Is TCR required for every drug?<\/strong><\/p>\n The term is primarily relevant for monoclonal antibodies and comparable biopharmaceuticals; the necessity arises from their properties and the safety strategy.<\/p>\n A tissue cross-reactivity study is an immunohistochemical investigation for monoclonal antibodies and other suitable biopharmaceuticals. It examines whether the test substance binds to structures other than its intended target structure within a spectrum of human tissues. The study aims to detect unintended tissue reactivity and can support the selection of a pharmacologically relevant animal species […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[27],"class_list":["post-8174","glossary","type-glossary","status-publish","hentry","glossary-cat-nichtklinik-pharmakologie"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8174\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8174"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n